Summary of the latest clinical progress and research results of daprostat tablets

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), mainly used to treat anemia related to chronic kidney disease (CKD). Anemia is a common complication in patients with chronic kidney disease, which significantly affects the patient's quality of life and prognosis. Traditional anemia treatment mainly relies on erythropoietin (ESA) injections, which involve inconvenient injections, immune reactions and other potential risks. Daprostat is administered orally to activate the erythropoiesis-stimulating mechanism in the body, bringing a new option for the treatment of anemia.

1. Key Results of Clinical Trials

In recent years, daprostat has shown good efficacy and safety in a number of key Phase III clinical trials and has become one of the new drugs for anemia treatment that attracts global attention. Representative trials include ASCEND-D and ASCEND-NHQ.

ASCEND-D is a large-scale randomized controlled trial evaluating the efficacy and safety of dapostat versus conventional ESA in patients with dialysis-dependent chronic kidney disease. The results showed that dapoxostat can effectively maintain hemoglobin within the target range, and compared with ESA, there is no significant difference in safety indicators such as cardiovascular events and adverse reactions. ASCEND-NHQ is mainly targeted at non-dialysis patients. Studies have confirmed that daprostat can also effectively improve anemia-related symptoms and improve patients’ quality of life. These studies laid the foundation for the widespread use of daplostat in different patient groups.

2. Pharmacological mechanism and advantages

Daprostat blocks the degradation of HIF-α by inhibiting prolyl hydroxylase, simulating a hypoxic environment, thereby increasing the secretion of endogenous erythropoietin (EPO) in the kidneys and liver. EPO is a key hormone that stimulates the production of red blood cells in the bone marrow, promoting the recovery of red blood cell numbers and increasing hemoglobin levels. Unlike the traditional ESA direct injection of erythropoietin, dapoxostat regulates the body's own hypoxia response mechanism, making the drug more natural and likely to have fewer side effects.

In addition, dapostat is an oral preparation, which is easy to use and improves patients' medication compliance. It is especially suitable for patients with chronic kidney disease who require long-term treatment. At the same time, some studies have pointed out that daprostat may also have a positive impact on the regulation of iron metabolism, promote the utilization of iron, and improve the treatment effect of anemia.

3. Approval and Market Dynamics

In February 2023, the U.S. Food and Drug Administration (FDA) officially approved daprostat (commercial product Named Jesduvroq (Jesduvroq) for the treatment of anemia in adults with chronic kidney disease receiving dialysis, marking the first approved oral HIF-PHI drug. This approval not only reflects the clinical verification of its efficacy and safety, but also brings a new option for anemia patients besides injection treatment.

Currently, daprostat has not been officially launched in the domestic market, nor has it been included in the medical insurance system. Therefore, domestic patients mainly learn about and come into contact with this drug through clinical trials or overseas channels. In overseas markets, in addition to the original drugs, some generic drugs have been launched. For example, the generic version of daprostat produced by Lucius Pharmaceuticals in Laos is 1mg*100 tablets. The price is relatively affordable, which greatly improves patient accessibility.

4. Future research directions and challenges

Although daprostat has shown good results in dialysis patients, future clinical research will still focus on its application in non-dialysis chronic kidney disease patients, as well as in a wider range of anemia patients. Researchers are evaluating its long-term safety, particularly the risk of cardiovascular events, and its efficacy in combination with other anemia treatments such as iron.

In addition, the differences in efficacy and tolerability of drugs in different groups (such as patients with diabetes and hypertension) are also continuously studied. As more real-world data accumulates, daplestat is expected to be included in more clinical guidelines and become one of the standard treatments for the management of anemia in chronic kidney disease.

Drug prices and medical insurance inclusion issues are also key to future promotion. Currently, it still takes time for dapostat to be launched in China and approved by medical insurance. Reasonable pricing and medical insurance coverage will directly affect patients’ accessibility and willingness to use it. Cooperation between pharmaceutical companies and regulatory agencies will help them reach patients more quickly.

As an innovative oral anemia treatment drug, dapoprimostat is emerging in the field of anemia treatment in chronic kidney disease due to its unique mechanism of action and good clinical performance. Clinical trial results show that it can effectively increase hemoglobin levels while maintaining good safety, especially providing a more convenient oral solution for long-term treatment. With global regulatory approval and marketing, daplestat is expected to change the treatment landscape for anemia patients. In the future, with the deepening of more research and clinical application, the role of daprostat in non-dialysis patients and the wider population will be clearer, and its market prospects are widely optimistic.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat